Loading clinical trials...

Copeptin Serum Level in Liver Transplant Recipients | Clinical Trials | Clareo Health

COMPLETED

Copeptin Serum Level in Liver Transplant Recipients

NCT03587623•Medical University of Warsaw

Summary

The study aim is to measure perioperative copeptin concentration in blood of liver transplant recipients and to assess whether there is a correlation between its level and hemodynamic derangement.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- Patient undergoing liver transplantation

Exclusion Criteria

•Serum creatinine \> 1,5 mg/dl
•Retransplantation
•Patient refusal
•CRRT or dialysis preoperatively

Locations (1)

I Klinika Anestezjologii WUM

Warsaw, Mazovian Voivodeship, Poland

Key Dates

Start Date

July 4, 2018

Primary Completion Date

January 31, 2020

Completion Date

January 31, 2020

Last Updated

August 19, 2020

Enrollment

ACTUAL participants

Conditions

Liver CirrhosisCopeptinLiver Transplant

Rectus-Intercostal Fascial Plane Block for Liver Transplantation Donors

NCT07233096

Liver TransplantationLiving Donor+1 more

View study

RECRUITING

Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion

NCT07315204

Liver Transplant Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITING